Literature DB >> 22155016

Autoantibodies in patients with chronic hepatitis C virus infection: pitfalls for the diagnosis of rheumatic diseases.

Carlo Palazzi1, Dan Buskila, Salvatore D'Angelo, Emilio D'Amico, Ignazio Olivieri.   

Abstract

Hepatitis C virus infection (HCV) is one of the best mimes in medicine. About 40-70% of patients suffering from this disorder develop at least one extra-hepatic disorder that can have a rheumatic nature (arthralgias, arthritis, vasculitis and sicca syndrome) and must be differentiated from the primitive rheumatic diseases. In addition, HCV infection can also alter the laboratory tests. Several alterations of first line laboratory tests can be usually found in both chronic HCV infection and chronic inflammatory rheumatic disorders. In the present review we analyze the interference of HCV in tests more specifically used in rheumatology: rheumatoid factor and other autoantibodies (ANA, anti-ENA, ANCA, anti-DNA, antiphospholipid, anti-CCP). In patients suffering from HCV infection, the diagnosis of connective tissue diseases (CTD) or rheumatoid arthritis (RA) should be made only when the detected symptoms or laboratory data are not inducible by HCV, otherwise only a diagnosis of "possible CTD" or "possible RA" should be considered.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22155016     DOI: 10.1016/j.autrev.2011.11.011

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  15 in total

Review 1.  Useful biomarkers for assessment of hepatitis C virus infection-associated autoimmune disorders.

Authors:  Deng-Ho Yang; Ling-Jun Ho; Jenn-Haung Lai
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

2.  Hepatitis C virus infection and its rheumatologic implications.

Authors:  Zeynel A Sayiner; Uzma Haque; Mohammad U Malik; Ahmet Gurakar
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-05

3.  Suspected and unsuspected factors in the multifaceted immunopathology of viral hepatitis.

Authors:  Carlo Selmi; Angela Ceribelli; John M Vierling
Journal:  Semin Immunopathol       Date:  2012-12-19       Impact factor: 9.623

Review 4.  Drug-induced glomerular disease: immune-mediated injury.

Authors:  Jonathan J Hogan; Glen S Markowitz; Jai Radhakrishnan
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-19       Impact factor: 8.237

5.  Anti-ENA antibody profiles in patients with hepatitis C virus infection.

Authors:  Christine M Litwin; Angela R Rourk
Journal:  J Clin Lab Anal       Date:  2017-06-12       Impact factor: 2.352

6.  Hepatitis B carrier state among SLE patients: case-control study.

Authors:  Omer Gendelman; Naim Mahroum; Doron Comaneshter; Pnina Rotman-Pikielny; Arnon D Cohen; Howard Amital; Michael Sherf
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 7.  Rheumatic manifestations of hepatitis C virus chronic infection: Indications for a correct diagnosis.

Authors:  Carlo Palazzi; Emilio D'Amico; Salvatore D'Angelo; Michele Gilio; Ignazio Olivieri
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

Review 8.  Human microbiome, infections, and rheumatic disease.

Authors:  Ana Clara Caminer; Rebecca Haberman; Jose U Scher
Journal:  Clin Rheumatol       Date:  2017-11-03       Impact factor: 3.650

Review 9.  Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection.

Authors:  Takashi Himoto; Tsutomu Masaki
Journal:  Clin Dev Immunol       Date:  2012-09-05

10.  Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study.

Authors:  Nicola Bizzaro; Elena Bartoloni; Gabriella Morozzi; Stefania Manganelli; Valeria Riccieri; Paola Sabatini; Matteo Filippini; Marilina Tampoia; Antonella Afeltra; Giandomenico Sebastiani; Claudia Alpini; Vittorio Bini; Onelia Bistoni; Alessia Alunno; Roberto Gerli
Journal:  Arthritis Res Ther       Date:  2013-01-22       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.